Search - tctmd.com

Displaying 81 - 100 of 189

Sort: Relevancy | Date

News Opinion CV Team Dispatch

October 2022 News Roundup

L.A. McKeown

October 01, 2022

News Conference News TCT 2022

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

Todd Neale

September 16, 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

Shelley Wood

September 07, 2022

News Opinion CV Team Dispatch

September 2022 News Roundup

L.A. McKeown

September 01, 2022

News Daily News

AHA, CRF Announce Partnership for 2022 Fall Meeting Sessions

Shelley Wood

August 15, 2022

News Opinion CV Team Dispatch

August 2022 News Roundup

L.A. McKeown

August 01, 2022

News Daily News

CMR Could Refine Early Management Decisions in Aortic Regurgitation

L.A. McKeown

July 27, 2022

News Daily News

Black and Hispanic Patients Not Accessing High-Volume TEER Centers

Michael O'Riordan

July 19, 2022

News Daily News

‘It’s All Cuts’: Cardiologists React to the 2023 CMS Proposed Rule

Yael L. Maxwell

July 15, 2022

News Opinion CV Team Dispatch

July 2022 News Roundup

L.A. McKeown

July 01, 2022

News Daily News

Minimalist Valve-in-Valve TMVR as Safe as Conventional Approach

Michael O'Riordan

June 21, 2022

News Daily News

COVID-19 Had Broad Global Effects on CV Care, Review Affirms

Todd Neale

June 02, 2022

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Todd Neale

May 31, 2022

News Conference News ESC Heart Failure 2022

Speech-Recognition Tool May Predict Worsening Congestion in HF

Shelley Wood

May 22, 2022

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

News Opinion CV Team Dispatch

May 2022 News Roundup

L.A. McKeown

May 01, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

L.A. McKeown

April 07, 2022

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2022

Caitlin E. Cox

April 01, 2022

Advertisement

October 2022 News Roundup

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

New Faces, New Formats, New Tech: What to Expect From TCT 2022

September 2022 News Roundup

AHA, CRF Announce Partnership for 2022 Fall Meeting Sessions

August 2022 News Roundup

CMR Could Refine Early Management Decisions in Aortic Regurgitation

Black and Hispanic Patients Not Accessing High-Volume TEER Centers

‘It’s All Cuts’: Cardiologists React to the 2023 CMS Proposed Rule

July 2022 News Roundup

Minimalist Valve-in-Valve TMVR as Safe as Conventional Approach

COVID-19 Had Broad Global Effects on CV Care, Review Affirms

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Speech-Recognition Tool May Predict Worsening Congestion in HF

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

May 2022 News Roundup

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

TCTMD’s Top 10 Most Popular Stories for March 2022

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content